Syndax Pharmaceuticals Inc
SNDX17.730USD
+2.010+12.79%
收盤 11/11, 16:00（美東）報價延遲15分鐘
1.54B總市值
虧損本益比TTM
關於 Syndax Pharmaceuticals Inc 公司
Syndax Pharmaceuticals, Inc. 是一家臨牀階段的生物製藥公司。該公司專注於開發癌症療法。其候選產品包括 revumenib 和 axatilimab。該公司正在開發 revumenib，這是一種強效、選擇性、小分子抑制劑，可抑制 menin-MLL 結合相互作用，用於治療 KMT2A 重排（也稱爲混合譜系白血病重排）、急性白血病（包括急性淋巴細胞白血病和急性髓細胞白血病 (AML)）和核磷蛋白 1（也稱爲 NPM1，突變體 A）。該公司還在探索使用 revumenib 治療實體瘤，特別是其在轉移性結直腸癌中的活性。該公司還在開發 axatilimab，這是一種單克隆抗體，可阻斷慢性移植物抗宿主病 (cGVHD) 以及特發性肺纖維化中的集落刺激因子 1 受體 (CSF-1R)。 Entinostat 是一種口服小分子候選產品，對癌細胞和免疫調節細胞有直接作用。
Syndax Pharmaceuticals Inc簡介
公司代碼SNDX
公司名稱Syndax Pharmaceuticals Inc
上市日期Mar 03, 2016
CEOMr. Michael A. Metzger
員工數量270
證券類型Ordinary Share
年結日Mar 03
公司地址730 Third Avenue
城市NEW YORK
上市交易所NASDAQ Global Select Consolidated
國家United States of America
郵編10017
電話17814191400
網址https://syndax.com/
公司代碼SNDX
上市日期Mar 03, 2016
CEOMr. Michael A. Metzger
Syndax Pharmaceuticals Inc公司高管
名稱
名稱/職務
職務
持股
持股變動
Mr. Michael A. Metzger
Mr. Michael A. Metzger
Chief Executive Officer, Director
Chief Executive Officer, Director
298.66K
--
Mr. Dennis G. Podlesak
Mr. Dennis G. Podlesak
Independent Chairman of the Board
Independent Chairman of the Board
127.33K
--
Mr. Keith A. Katkin, CPA
Mr. Keith A. Katkin, CPA
Independent Director
Independent Director
75.00K
+15.38%
Mr. Steven (Steve) Closter
Mr. Steven (Steve) Closter
Chief Commercial Officer
Chief Commercial Officer
70.90K
--
Mr. Pierre Legault, CPA
Mr. Pierre Legault, CPA
Independent Director
Independent Director
65.00K
-10.96%
Mr. Nicholas A.J. Botwood
Mr. Nicholas A.J. Botwood
Head - Research and Development, Chief Medical Officer
Head - Research and Development, Chief Medical Officer
--
--
Ms. Jennifer A. Jarrett
Ms. Jennifer A. Jarrett
Independent Director
Independent Director
--
--
Dr. Aleksandra Rizo, M.D., Ph.D.
Dr. Aleksandra Rizo, M.D., Ph.D.
Independent Director
Independent Director
--
--
Mr. Keith A. Goldan, CPA
Mr. Keith A. Goldan, CPA
Chief Financial Officer
Chief Financial Officer
--
--
Dr. Martin H. Huber, M.D.
Dr. Martin H. Huber, M.D.
Independent Director
Independent Director
--
--
查看更多
名稱
名稱/職務
職務
持股
持股變動
Mr. Michael A. Metzger
Mr. Michael A. Metzger
Chief Executive Officer, Director
Chief Executive Officer, Director
298.66K
--
Mr. Dennis G. Podlesak
Mr. Dennis G. Podlesak
Independent Chairman of the Board
Independent Chairman of the Board
127.33K
--
Mr. Keith A. Katkin, CPA
Mr. Keith A. Katkin, CPA
Independent Director
Independent Director
75.00K
+15.38%
Mr. Steven (Steve) Closter
Mr. Steven (Steve) Closter
Chief Commercial Officer
Chief Commercial Officer
70.90K
--
Mr. Pierre Legault, CPA
Mr. Pierre Legault, CPA
Independent Director
Independent Director
65.00K
-10.96%
Mr. Nicholas A.J. Botwood
Mr. Nicholas A.J. Botwood
Head - Research and Development, Chief Medical Officer
Head - Research and Development, Chief Medical Officer
--
--
收入明細
暫無數據
暫無數據
業務
地區
暫無數據
股東統計
更新時間: 8月16日 週六
更新時間: 8月16日 週六
持股股東
股東類型
持股股東
持股股東
佔比
Kynam Capital Management LP
9.80%
BlackRock Institutional Trust Company, N.A.
8.70%
Goldman Sachs & Company, Inc.
5.98%
The Vanguard Group, Inc.
5.89%
Eversept Partners, LP
4.68%
其他
64.96%
持股股東
持股股東
佔比
Kynam Capital Management LP
9.80%
BlackRock Institutional Trust Company, N.A.
8.70%
Goldman Sachs & Company, Inc.
5.98%
The Vanguard Group, Inc.
5.89%
Eversept Partners, LP
4.68%
其他
64.96%
股東類型
持股股東
佔比
Hedge Fund
48.37%
Investment Advisor
34.79%
Investment Advisor/Hedge Fund
21.09%
Research Firm
11.71%
Venture Capital
4.19%
Individual Investor
1.30%
Pension Fund
0.77%
Bank and Trust
0.47%
Insurance Company
0.03%
機構持股
更新時間: 10月1日 週三
更新時間: 10月1日 週三
報告期間
機構數
持股數
持股佔比
持股變動
2025Q3
456
105.70M
121.61%
-16.72M
2025Q2
453
106.14M
123.25%
-9.50M
2025Q1
465
105.51M
122.65%
-11.55M
2024Q4
466
101.18M
117.63%
-2.44M
2024Q3
454
91.99M
107.96%
-12.90M
2024Q2
424
90.42M
106.49%
-16.61M
2024Q1
417
93.25M
109.83%
-11.76M
2023Q4
407
91.08M
107.54%
+9.06M
2023Q3
394
77.71M
113.61%
-12.98M
2023Q2
385
77.69M
113.93%
-12.13M
查看更多
股東持股明細
名稱
持股數
佔比
持股變動
變動比例
公告日期
Kynam Capital Management LP
8.52M
9.89%
--
--
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
7.56M
8.77%
+745.47K
+10.94%
Jun 30, 2025
Goldman Sachs & Company, Inc.
5.20M
6.03%
+1.74M
+50.14%
Jun 30, 2025
The Vanguard Group, Inc.
5.01M
5.82%
+158.25K
+3.26%
Jun 30, 2025
Eversept Partners, LP
4.07M
4.72%
-146.91K
-3.49%
Jun 30, 2025
BofA Global Research (US)
3.84M
4.46%
+967.87K
+33.71%
Jun 30, 2025
State Street Investment Management (US)
3.44M
4%
-528.98K
-13.32%
Jun 30, 2025
StemPoint Capital LP
2.37M
2.75%
+774.04K
+48.42%
Jun 30, 2025
Franklin Advisers, Inc.
2.33M
2.71%
+296.77K
+14.57%
Jun 30, 2025
Point72 Asset Management, L.P.
2.13M
2.47%
-1.88M
-46.93%
Jun 30, 2025
查看更多
持股ETF
更新時間: 11月6日 週四
更新時間: 11月6日 週四
機構名稱
佔比
Tema Oncology ETF
2.12%
Virtus LifeSci Biotech Clinical Trials ETF
1.04%
SPDR S&P Biotech ETF
0.56%
Simplify Health Care ETF
0.35%
Inspire Small/Mid Cap ESG ETF
0.32%
Direxion Daily S&P Biotech Bull 3X Shares
0.29%
ProShares Ultra Nasdaq Biotechnology
0.14%
Invesco Nasdaq Biotechnology ETF
0.13%
iShares Biotechnology ETF
0.12%
iShares Russell 2000 Growth ETF
0.07%
查看更多
Tema Oncology ETF
佔比2.12%
Virtus LifeSci Biotech Clinical Trials ETF
佔比1.04%
SPDR S&P Biotech ETF
佔比0.56%
Simplify Health Care ETF
佔比0.35%
Inspire Small/Mid Cap ESG ETF
佔比0.32%
Direxion Daily S&P Biotech Bull 3X Shares
佔比0.29%
ProShares Ultra Nasdaq Biotechnology
佔比0.14%
Invesco Nasdaq Biotechnology ETF
佔比0.13%
iShares Biotechnology ETF
佔比0.12%
iShares Russell 2000 Growth ETF
佔比0.07%
分紅派息
近5年累計派現
0.00
美元
公告日期
分紅計劃
股權登記日
現金發放日
除權除息日
暫無數據
拆合股
公告日期
類型
比率
暫無數據
公告日期
類型
比率
暫無數據
